Literature DB >> 18772312

Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.

Paola Secchiero1, Elisabetta Melloni, Federica Corallini, Antonio Paolo Beltrami, Francesco Alviano, Daniela Milani, Federica D'Aurizio, Maria Grazia di Iasio, Daniela Cesselli, Gian Paolo Bagnara, Giorgio Zauli.   

Abstract

Adult multipotent stromal cells (MSCs), also known as mesenchymal stem cells, represent an important source of cells for the repair of a number of damaged tissues. Both bone marrow (BM)-derived and amniotic MSCs expressed detectable surface levels of two (tumor necrosis factor-related apoptosis-inducing ligand receptor 2 [TRAIL-R2] and TRAIL-R4) of four transmembrane TRAIL receptors. Although the best-characterized activity of TRAIL-R2 is the transduction of apoptotic signals, neither recombinant TRAIL (rTRAIL) nor infection with an adenovirus-expressing TRAIL induced cytotoxic effects on MSCs. Moreover, whereas rTRAIL did not affect proliferation or differentiation of MSCs along the osteogenic and adipogenic lineages, it significantly promoted the migration of human MSCs in range of concentrations comparable to that of soluble TRAIL in human plasma (100 pg/ml). Since rTRAIL induced the rapid phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in MSC cultures and pretreatment with pharmacological inhibitors of the ERK1/2 pathway efficiently counteracted the rTRAIL-induced human MSC migration, these data indicate that ERK1/2 is involved in mediating the ability of rTRAIL to stimulate MSC migration. Taking into consideration that the soluble factors able to induce MSC migration have not been extensively characterized, our current data indicate that the TRAIL/TRAIL-R system might play an important role in the biology of MSCs. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18772312     DOI: 10.1634/stemcells.2008-0512

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  25 in total

1.  Survival of aging CD264+ and CD264- populations of human bone marrow mesenchymal stem cells is independent of colony-forming efficiency.

Authors:  Sean D Madsen; Sean H Jones; H Alan Tucker; Margaret K Giler; Dyllan C Muller; Carson T Discher; Katie C Russell; Georgina L Dobek; Mimi C Sammarco; Bruce A Bunnell; Kim C O'Connor
Journal:  Biotechnol Bioeng       Date:  2019-11-12       Impact factor: 4.530

2.  Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.

Authors:  Giulia Grisendi; Rita Bussolari; Elena Veronesi; Serena Piccinno; Jorge S Burns; Giorgio De Santis; Pietro Loschi; Marco Pignatti; Fabrizio Di Benedetto; Roberto Ballarin; Carmela Di Gregorio; Valentina Guarneri; Lino Piccinini; Edwin M Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici
Journal:  Am J Cancer Res       Date:  2011-05-28       Impact factor: 6.166

3.  Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle.

Authors:  Mohsen Khorashadizadeh; Masoud Soleimani; Hossein Khanahmad; Ali Fallah; Mahmood Naderi; Mohammadreza Khorramizadeh
Journal:  Tumour Biol       Date:  2015-01-15

Review 4.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

5.  Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL.

Authors:  Arianna Gonelli; Oriano Radillo; Sara Drioli; Erika Rimondi; Paola Secchiero; Gian Maria Bonora
Journal:  Invest New Drugs       Date:  2010-12-02       Impact factor: 3.850

Review 6.  The therapeutic potential of TRAIL receptor signalling in cancer cells.

Authors:  R Yerbes; C Palacios; A López-Rivas
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

Review 7.  Recent Progress in Stem Cell Therapy for Diabetic Nephropathy.

Authors:  Yang Liu; Sydney C W Tang
Journal:  Kidney Dis (Basel)       Date:  2015-12-05

8.  Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.

Authors:  Vivian Labovsky; Leandro Marcelo Martinez; María de Luján Calcagno; Kevin Mauro Davies; Hernán García-Rivello; Alejandra Wernicke; Leonardo Feldman; María Belén Giorello; Ayelén Matas; Francisco Raúl Borzone; Scott C Howard; Norma Alejandra Chasseing
Journal:  Tumour Biol       Date:  2016-07-27

9.  The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma.

Authors:  Bo Zhang; Hong Shan; Dan Li; Zheng-Ran Li; Kang-Shun Zhu; Zai-Bo Jiang
Journal:  Cancer Biol Ther       Date:  2012-08-24       Impact factor: 4.742

10.  TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL.

Authors:  Federica Corallini; Paola Secchiero; Antonio Paolo Beltrami; Daniela Cesselli; Elisa Puppato; Roberto Ferrari; Carlo Alberto Beltrami; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2010-01-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.